pany. We look forward to continuing to work with FDA as we prepare a number of clinical studies for disease states with high unmet clinical needs." Robert Sexauer, EVP of Clinical Development stated "We can now begin to move forward with our plans for in- human clinical studies such as lower limb ischemia by ap

od and Drug Administration ("FDA") standards. We have added two new members to our staff, Ms. Sarah Young, our Quality Assurance Director, and Mr. Robert Sexauer, our EVP of Clinical Research. These skilled professionals have brought many years of experience with them to the Company which has allowed us to b